The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-12 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
are convenient for the patients who have difficulty in swallowing (children, old people, bed-ridden and psychiatric patients); are fast to absorb; don't require water to consume; have good taste (mouth feel); don't provoke choking or suffocation; have high microbial resistance ("due to the low moisture content in the final product, the Zydis formulation does not allow microbial growth").
==== Serious illness ==== Serious illness may result in low blood sugar. Severe disease of many organ systems can cause hypoglycemia as a secondary problem. Hypoglycemia is especially common in those in the intensive care unit or those in whom food and drink is withheld as a part of their treatment plan. Sepsis, a common cause of hypoglycemia in serious illness, can lead to hypoglycemia through many ways. In a state of sepsis, the body uses large amounts of glucose for energy. Glucose use is further increased by cytokine production. Cytokines are a protein produced by the body in a state of stress, particularly when fighting an infection. Cytokines may inhibit glucose production, further decreasing the body's energy stores. Finally, the liver and kidneys are sites of glucose production, and in a state of sepsis those organs may not receive enough oxygen, leading to decreased glucose production due to organ damage. Other causes of serious illness that may cause hypoglycemia include liver failure and kidney failure. The liver is the main site of glucose production in the body, and any liver failure or damage will lead to decreased glucose production. While the kidneys are also sites of glucose production, their failure of glucose production is not significant enough to cause hypoglycemia. Instead, the kidneys are responsible for removing insulin from the body, and when this function is impaired in kidney failure, the insulin stays in circulation longer, leading to hypoglycemia.
=== Bacteria === Melatonin is produced by α-proteobacteria and photosynthetic cyanobacteria. There is no report of its occurrence in archaea which indicates that melatonin originated in bacteria most likely to prevent the first cells from the damaging effects of oxygen in the primitive Earth's atmosphere. Novo Nordisk have used genetically modified Escherichia coli to produce melatonin.
Sources: en.wikipedia.org
== Adaptations == In 2000, Yahoo! reported that MGM and actor/director Tom Hanks were in discussions regarding adapting both 2061: Odyssey Three and 3001: The Final Odyssey into movies, with Hanks reportedly to play Frank Poole in the 3001 film. An update in 2001 stated that there was no further development on the project. On 3 November 2014, it was reported that the US TV channel Syfy had ordered a miniseries adaptation of 3001: The Final Odyssey into production, planned for broadcast in 2015. The miniseries would be executive-produced by Ridley Scott, David W. Zucker and Stuart Beattie; the latter would also be the primary script-writer. The estates of both Clarke and 2001: A Space Odyssey director Stanley Kubrick were reported as having "offered their full support", but the extent of their involvement was not known at the time. In February 2016, within Syfy's press release for its television pilot Prototype, other series including the Final Odyssey series were mentioned as being in development. However, to date, no further progress has been made. The plot of Futurama has similarities, with the character of Fry being frozen for 1000 years (albeit in 1999) and waking in the year 3000.
==== MeSH D08.244.453 – cytochrome p-450 enzyme system ==== MeSH D08.244.453.040 – aryl hydrocarbon hydroxylases MeSH D08.244.453.040.050 – aniline hydroxylase MeSH D08.244.453.040.110 – benzopyrene hydroxylase MeSH D08.244.453.040.555 – cytochrome p-450 cyp1a1 MeSH D08.244.453.040.777 – cytochrome p-450 cyp1a2 MeSH D08.244.453.040.888 – cytochrome p-450 cyp2b1 MeSH D08.244.453.040.944 – cytochrome p-450 cyp2d6 MeSH D08.244.453.040.972 – cytochrome p-450 cyp2e1 MeSH D08.244.453.040.986 – cytochrome p-450 cyp3a MeSH D08.244.453.085 – camphor 5-monooxygenase MeSH D08.244.453.915 – steroid hydroxylases MeSH D08.244.453.915.050 – aldosterone synthase MeSH D08.244.453.915.099 – aromatase MeSH D08.244.453.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.244.453.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.244.453.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.244.453.915.720 – steroid 11-beta-hydroxylase MeSH D08.244.453.915.730 – steroid 12-alpha-hydroxylase MeSH D08.244.453.915.737 – steroid 16-alpha-hydroxylase MeSH D08.244.453.915.748 – steroid 17-alpha-hydroxylase MeSH D08.244.453.915.760 – steroid 21-hydroxylase MeSH D08.244.453.957 – trans-cinnamate 4-monooxygenase
=== Usman Abboud === Usman Abboud (Amir El-Masry) is the assistant to Kaspar Zenden, Clement's sole client. Usman puts on a professional facade for Kaspar, pretending to be conservative and abstinent from alcohol and drugs, but reveals himself as a hard-partying, homosexual playboy to Robert and later Greg. After Clement is fired from Pierpoint, Usman tells Robert that Kaspar no longer wishes to continue his relationship with Pierpoint.
Wallace Michael Shawn (born November 12, 1943) is an American actor, essayist, and writer. He is known for playing Vizzini in The Princess Bride (1987), Mr. Hall in Clueless (1995), and Dr. John Sturgis in Young Sheldon (2017–2024), and for voicing Rex the Dinosaur in the Toy Story franchise (1995–2026). Shawn also appeared in The Bostonians (1984), Prick Up Your Ears (1987), Scenes from the Class Struggle in Beverly Hills (1989), Vanya on 42nd Street (1994), The Haunted Mansion (2003), The Incredibles (2004), Southland Tales (2006), The Double (2013), and Marriage Story (2019). He appeared in six Woody Allen films including Manhattan (1979), Radio Days (1987), and Rifkin's Festival (2020). His television work includes recurring roles as Arnie Ross in Taxi (1978-1983), Jeff Engels in The Cosby Show (1987–1991), Grand Nagus Zek in Star Trek: Deep Space Nine (1993–1999), Cyrus Rose in Gossip Girl (2008–2012), and Father Frank Ignatius in Evil (2022–2024). Shawn is also a playwright; his plays include the Obie Award–winning Aunt Dan and Lemon (1985), The Designated Mourner (1996), Grasses of a Thousand Colors (2008), and What We Did Before Our Moth Days (2026). With Andre Gregory, he wrote and starred in the 1981 drama My Dinner with Andre. He played the title role in A Master Builder (2013), a film adaptation of Henrik Ibsen's 1892 play. Haymarket Books published his books Essays (2009) and Night Thoughts (2017).
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.